Monterey Herald

California considers declaring common pain killer carcinogen

- By Adam Beam

SACRAMENTO >> A fight is coming to California over whether to list one of the world’s most common overthe-counter drugs as a carcinogen, echoing recent high-profile battles over things like alcohol and coffee.

The drug is acetaminop­hen, known outside the U.S. as paracetamo­l and used to treat pain and fevers. It is the basis for more than 600 prescripti­on and over-the-counter medication­s for adults and children, found in well-known brands like Tylenol, Excedrin, Sudafed, Robitussin and Theraflu.

Acetaminop­hen has been available in the U.S. without a prescripti­on since 1955. Concerns about its potential link to cancer come from its relationsh­ip to another drug: phenacetin. That drug, once a common treatment for headaches and other ailments, was banned by the FDA in 1983 because it caused cancer.

State regulators have reviewed 133 studies about acetaminop­hen, all of which were published in peer-reviewed journals. Some studies reported an increased risk of some types of cancers, while others did not. Overall, the review noted acetaminop­hen has been difficult to examine because it is hard to isolate it from other variables that could contribute to cancer, such as smoking.

A state law known as Propositio­n 65 says California must warn people of any chemical known to cause cancer or reproducti­ve toxicity. The state’s list has grown to about 900 chemicals, including toxic pesticides and flame retardants, and is more extensive than any in the U.S. Some critics say California regulators have been overzealou­s, requiring warning labels for countless products that confuse instead of inform consumers when the risk of cancer is disputed.

Supporters of Prop 65 say it protects not only California­ns but consumers nationwide by compelling manufactur­ers to make products safer.

Evidence for acetaminop­hen’s link to cancer has been weak enough that the Internatio­nal Agency for Research on Cancer declined to list it as a possible carcinogen following reviews in 1990 and 1999. The U.S. Food and Drug Administra­tion has warned state officials that labeling acetaminop­hen as cancer-causing would be “false and misleading” and also illegal under federal law.

A panel of scientists appointed by the governor can add chemicals to this list. In 2011, the panel voted to make acetaminop­hen a “high priority” for considerat­ion because it believed there was relevant evidence to consider, according to Sam Delson, spokesman for the California Office of Environmen­tal Health Hazard Assessment.

The review process has been slow, but the panel is scheduled to have a public hearing on the listing this spring after the public comment period closes on Jan. 27.

“It’s a difficult issue because it’s a very commonly used drug. But that doesn’t make any difference. That’s not what our mandate is,” said Thomas Mack, chairman of the Carcinogen Identifica­tion Committee and a professor of preventive medicine at the University of Southern California.

Adding a chemical to the list can have broad repercussi­ons. After the state listed glyphosate — widely known as the weed killer Roundup — as a carcinogen in 2017, a jury ordered the company that makes Roundup to pay a California couple with cancer more than $2 billion. A judge later reduced that award to $87 million. That’s just one of the estimated 13,000 pending lawsuits involving the chemical.

 ?? CHRIS CARLSON — THE ASSOCIATED PRESS ?? This photo shows generic acetaminop­hen capsules in Santa Ana.
CHRIS CARLSON — THE ASSOCIATED PRESS This photo shows generic acetaminop­hen capsules in Santa Ana.

Newspapers in English

Newspapers from United States